Use your antibodies-online credentials, if available.
Il n’y a pas de produits dans votre liste de comparaison.
Votre panier est vide.
Afficher toutes les espèces
Afficher tous les synonymes
Sélectionnez vos espèces et l'application
anti-Mouse (Murine) Anticorps:
anti-Rat (Rattus) Anticorps:
Vous arrivez à notre recherche pré-filtrée.
these data support a role for the novel PP2Ac (Montrer PPP2CA Anticorps)-CIN85 complex in supporting integrin-dependent platelet function by dampening the phosphatase activity.
CIN85 promotes recycling of TGF-beta (Montrer TGFB1 Anticorps) receptors and thereby positively regulates TGF-beta (Montrer TGFB1 Anticorps) signaling.
we demonstrate that SEPT9 (Montrer SEPT9 Anticorps) negatively regulates EGFR (Montrer EGFR Anticorps) degradation by preventing the association of the ubiquitin ligase Cbl (Montrer CBL Anticorps) with CIN85, resulting in reduced EGFR (Montrer EGFR Anticorps) ubiquitylation
Results support the model that Cbl (Montrer CBL Anticorps)-CIN85-endophilin complex is not required for efficient internalization of EGFR (Montrer EGFR Anticorps), a prototype RTK.
Multiple molecular forms of adaptor protein Ruk/CIN85 specifically associate with different subcellular compartments in human breast adenocarcinoma cell line.
LOX (Montrer LOX Anticorps)-PP interacts with CIN85 via a novel SH3-binding motif and this association reduces CIN85-promoted invasion by breast cancer cells.
an FRS2beta (Montrer FRS3 Anticorps)-CIN85/CD2AP (Montrer Cd2ap Anticorps)-Cbl (Montrer CBL Anticorps) axis for downregulation of ErbB2 (Montrer ERBB2 Anticorps) may regulate ErbB2 (Montrer ERBB2 Anticorps) protein levels in physiological and pathological settings
Data show that EGFR (Montrer EGFR Anticorps) activation leads to a pronounced src (Montrer SRC Anticorps)-mediated tyrosine phosphorylation of CIN85 that subsequently influences EGFR (Montrer EGFR Anticorps) ubiquitination.
this study indicates that high levels of Ruk(l)/CIN85 contribute to the conversion of breast adenocarcinoma cells into a more malignant phenotype via modulation of the Src (Montrer SRC Anticorps)/Akt (Montrer AKT1 Anticorps) pathway.
Data show that CIN85 (c-Cbl interacting protein of 85 kDa) is constitutively associated with c-Cbl (Montrer CBL Anticorps), Cbl-b, and B-cell linker (Montrer BLNK Anticorps) in B cells.
CIN85/RukL is involved in endocytosis of nephrin (Montrer NPHS1 Anticorps) in podocytes under diabetic conditions, causing podocyte depletion and promoting proteinuria. CIN85/RukL expression therefore shows potential to be a novel target for antiproteinuric therapy in diabetes.
Dab1 (Montrer DAB1 Anticorps) mediated the association of CIN85 with ApoER2 (Montrer LRP8 Anticorps) or VLDLR (Montrer VLDLR Anticorps) in neurons.
Data suggest that Ser587 Cin85 phosphomimetic mutant protein shows dramatically reduced binding to Dab1 (Montrer DAB1 Anticorps) (disabled protein 1) (without affecting binding to CapZ (Montrer CAPZA1 Anticorps)).
Sh3kbp1 is SUMOylated by SUMO-1 (Montrer SUMO1 Anticorps), -2, and -3 and that SUMOylation is enhanced in the presence of Cd2ap (Montrer Cd2ap Anticorps).
the interaction between SHIP-1 (Montrer INPP5D Anticorps) and CIN85 might synergistically facilitate the down-regulation of phosphatidylinositol-3,4,5-trisphosphate levels.
Live cell imaging and co-immunoprecipitation experiments confirmed that both SLP65 (Montrer BLNK Anticorps) and CIN85 are both required for the onset and progression phases of B-cell antigen receptor signal transduction.
a B cell-specific deletion of CIN85 led to impaired T cell-independent type II antibody responses in vivo and diminished IKK-beta (Montrer IKBKB Anticorps) activation and cellular responses to B (Montrer TDO2 Anticorps) cell receptor cross-linking in vitro
Coexpression of CIN85/Ruk(L) with CD2AP (Montrer Cd2ap Anticorps) led to a decreased binding of CIN85/Ruk(L) to nephrin (Montrer NPHS1 Anticorps) and podocin, which indicates a functional competition between CD2AP (Montrer Cd2ap Anticorps) and CIN85/Ruk(L).
Data indicate an important function of CIN85 (SH3KBP1) in the regulation of dopamine D2 receptor (Montrer DRD2 Anticorps) functions and provide a molecular explanation for the hyperactive behaviour of CIN85(Deltaex2) mice.
CIN85 participates in Cbl-b-mediated down-regulation of receptor tyrosine kinases
This gene encodes an adapter protein that contains three N-terminal Src homology domains, a proline rich region and a C-terminal coiled-coil domain. The encoded protein facilitates protein-protein interactions and has been implicated in numerous cellular processes including apoptosis, cytoskeletal rearrangement, cell adhesion and in the regulation of clathrin-dependent endocytosis. Alternate splicing results in multiple transcript variants.
SH3-domain kinase binding protein 1
, SH3 domain-containing kinase-binding protein 1-like
, CD2-binding protein 3
, SH3 domain-containing kinase-binding protein 1
, Src family kinase-binding protein 1
, c-Cbl-interacting protein
, cbl-interacting protein of 85 kDa
, human Src family kinase-binding protein 1
, migration-inducing gene 18
, src-related kinase binding protein-1
, SH3-containing, expressed in tumorigenic astrocytes
, Sh3 containing, expressed in astrocytes
, regulator of ubiquitous kinase
, SH3 domain-containing adapter protein